Stock Price & Analysis

Sell Kenvue stock as it faces uncertainty from activist pressure and strategic changes. Hold until more clarity emerges on the company's direction.

Kenvue (KVUE) stock is predicted to reach $24.20 by the end of 2025, driven by potential strategic changes and moderate analyst expectations. The stock faces resistance at $24.10 and $24.49, with support at $22.85 and $22.46.

The S1 support level for KVUE Stock is $22.99 ,The R1 resistant level for KVUE Stock is $23.96.

As of the end of day on 2025-04-02, the price of KVUE Stock was $23.81.

The target price for KVUE Stock according to analyst rating is 24.18, with the highest price target at 29.00 and the lowest at 21.00. Analysts have a Moderate Buy rating on KVUE Stock overall.

The market cap of KVUE is $45.8B.

KVUE appears to be overvalued based on limited data. Its price of $23.42 lacks support from provided financials, and without earnings or revenue data, its valuation metrics are unclear. There's no recent news or analyst sentiment available on KVUE, making it difficult to assess its true value.

Kenvue Inc. is a consumer health company. The Company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include Pain Care; Cough, Cold, and Allergy; and Other Self Care (Digestive Health; Smoking Cessation; Eye Care; and Other). The Skin Health and Beauty segment's product categories include face and body care and hair, sun, and others. The Essential Health segment's product categories include oral care, baby care and other essential health (women’s health, wound care, and other). Its differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, Band-Aid, Aveeno, Zyrtec, and Nicorette. The Company has a global footprint through which it sells and distributes its product portfolio in more than 165 countries across its four regions. The four region consists of North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).

Based on current trends and strategic developments, Kenvue (KVUE) stock is predicted to trade between $15 and $40 by 2030. The stock's potential upside is driven by successful restructuring and asset optimization, while downside risks stem from execution challenges and market competition.

KVUE has a total of 22000 employees.